Granular Therapeutics Ltd
In many chronic inflammatory diseases, mast cells are central drivers of pathology. The paucity of mast cell-selective drugs leaves a huge unmet medical need in this area. Targeting of mast cells via indiscriminate blocking of c-KIT signalling, while potentially efficacious, can lead to severe, dose-limiting bone marrow suppression. Granular’s approach targets mast cells specifically & powerfully, for top-down, disease-modifying immune modulation with improved safety profile.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Granular Therapeutics Ltd
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Granular Therapeutics Ltd
1 distinct titles indexed · top 1 shown.
- 1é é
Sign up to unlock all 1 contacts at Granular Therapeutics Ltd
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Granular Therapeutics Ltd
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.